Page last updated: 2024-12-06

daunorubicin hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID62770
CHEMBL ID1563
CHEBI ID31456
SCHEMBL ID4444
MeSH IDM0361543

Synonyms (116)

Synonym
nsc-82151
daunomycin hydrochloride
rubidomycin hydrochloride
daunomycin, hydrochloride
rp 13057 hydrochloride
daunorubicin hcl
daunoblastin
ondena
daunorubicin hydrochloride
23541-50-6
smr000058559
MLS000069508 ,
wp900 hydrochloride, >=95% (hplc), solid
ccris 915
(1s,3s)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside hydrochloride
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s-cis)-, hydrochloride
einecs 245-723-4
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trhydroxy-1-methoxy-, hydrochloride, (8s,10s)-
daunomycin chlorohydrate
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl))oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s-cis)-, hydrochloride
daunoblastina
ai3-44887
c27h29no10.hcl
smr000768722
MLS001336042 ,
cerubidine
ndc 0082-4155
daunomycin hcl
NCGC00024246-03
daunoblastine
daunoxome
daunorubicin hydrochloride, meets usp testing specifications
D01264
daunorubicin hydrochloride (jp17/usp)
cerubidine (tn)
(1s,3s)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-l-lyxo-hexopyranoside hydrochloride
hydrochloride, daunorubicin
daunorubicin hydrochloride, >=90% (hplc)
MLS002222263
rp-13057
fi-6339 hydrochloride
rp-13057 hydrochloride
fi 6339 hydrochloride
rp 13057 [as the base)
daunorubicin (as hydrochloride)
fi 6339 [as the base]
CHEMBL1563
sr-01000000033
SR-01000000033-6
dtxsid0033382 ,
NCGC00258711-01
tox21_201159
dtxcid8013382
daunorubicin hydrochloride;(8s,10s)-8-acetyl-10-[[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy]-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
A816764
AKOS015920259
CCG-39942
daunorubicin hydrochloride [usan:usp:jan]
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8s,10s)-
unii-ud984i04lz
rp 13057 [as the base]
ud984i04lz ,
daunorubicin (hydrochloride)
HY-13062
CS-1271
daunorubicinol hydrochloride
S3035
(1s,3s)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranoside hydrochloride
daunorubicin hydrochloride [vandf]
daunorubicin hydrochloride [usp-rs]
daunorubicin hydrochloride [mi]
daunorubicin hydrochloride [who-dd]
daunorubicin hydrochloride [jan]
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl))oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s-cis)-, hydrochloride
daunorubicin hydrochloride [usp impurity]
daunorubicin hydrochloride [mart.]
daunorubicin hydrochloride [orange book]
daunorubicin hydrochloride [usan]
daunorubicin hydrochloride [ep monograph]
daunorubicin hydrochloride [usp monograph]
SCHEMBL4444
KS-5149
(8s,10s)-8-acetyl-10-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
GUGHGUXZJWAIAS-QQYBVWGSSA-N
mfcd04974507
sr-05000001600
daunorubicin hydrochloride, united states pharmacopeia (usp) reference standard
daunorubicin hydrochloride, european pharmacopoeia (ep) reference standard
SR-05000001600-3
CHEBI:31456
(8s,10s)-8-acetyl-10-((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
(8s,10s)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyransoyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride
HB4376
daunorubicin hcl (daunomycin hcl)
BD164356
daunorubicin hydrochloride; rp 13057 hydrochloride; daunomycin
EX-A2649
(8s-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride
daunorubicin,(s)
daunomycin; rp 13057; rubidomycin
Q27291034
daunorubicin hcl- bio-x
(8s,10s)-8-acetyl-10-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dionehydrochloride
daunorubicini hydrochloridum
daunorubicin hydrochloride (usp-rs)
daunorubicin hydrochloride (mart.)
daunorubicin.hcl
daunorubicin hydrochloride (ep monograph)
l-lyxo-hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-,hydrochloride
daunorubicin hydrochloride (usp impurity)
cloridrato de daunorubicina
rubilem
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8s-cis)-
daunorubicin hydrochloride (usan:usp:jan)
(2s,4s)-2-acetyl-4-(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyloxy)-2,5,12-trihydroxy-7-methoxy-1,2,3,4-tetrahydrotetracene-6,11-dione monohydrochloride
daunorubicin hydrochloride (usp monograph)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anthracyclineAnthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (122)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency25.11890.003245.467312,589.2998AID2517
Chain A, Breast cancer type 1 susceptibility proteinHomo sapiens (human)Potency15.84891.258920.440939.8107AID892
Chain A, Beta-lactamaseEscherichia coli K-12Potency31.62280.044717.8581100.0000AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.55940.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency39.81070.631035.7641100.0000AID504339
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency35.48130.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency35.96610.007215.758889.3584AID1224835; AID588342
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency37.99100.002541.796015,848.9004AID1347395; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency1.00000.01846.806014.1254AID624417
WRNHomo sapiens (human)Potency13.75380.168331.2583100.0000AID651768; AID720497
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency20.48183.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.19400.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency4.08230.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency3.26430.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency5.62340.031637.5844354.8130AID743255
SMAD family member 3Homo sapiens (human)Potency4.08230.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency0.01320.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.47190.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency14.55000.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency11.67230.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency0.56230.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency1.37690.013326.981070.7614AID1346978
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.87100.00137.762544.6684AID2120; AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.99530.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency43.78540.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency25.90600.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency10.15840.000417.946075.1148AID1346784; AID1346795; AID1347036
regulator of G-protein signaling 4Homo sapiens (human)Potency56.23410.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency6.30960.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency15.46910.000214.376460.0339AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.64650.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency12.75740.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.93250.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency18.96040.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency8.68760.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.00630.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080
67.9K proteinVaccinia virusPotency10.61010.00018.4406100.0000AID720579; AID720580
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency35.48130.707936.904389.1251AID504333
P53Homo sapiens (human)Potency3.98110.07319.685831.6228AID504706
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency29.47120.001024.504861.6448AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency8.78380.001019.414170.9645AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency4.89440.023723.228263.5986AID588541; AID743223
caspase-3Homo sapiens (human)Potency1.37690.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency0.07310.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency35.48130.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency5.52760.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.61500.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency42.81610.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency1.10310.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency24.69780.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency28.75060.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency4.88540.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency29.55670.540617.639296.1227AID2528; AID2585; AID720503
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency0.31620.01262.451825.0177AID485313
tumor necrosis factorHomo sapiens (human)Potency13.33320.375823.492842.1632AID651757
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency31.24310.010039.53711,122.0200AID1469; AID1479; AID588545; AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency0.79430.794321.275750.1187AID624246
caspase-3Cricetulus griseus (Chinese hamster)Potency4.88540.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.26780.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency53.91580.042027.378961.6448AID743210; AID743228
DNA polymerase betaHomo sapiens (human)Potency28.18380.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID1454
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency44.66844.466824.832944.6684AID651749
flap endonuclease 1Homo sapiens (human)Potency33.80780.133725.412989.1251AID720498
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency10.00000.65619.452025.1189AID463254
ras-related protein Rab-9AHomo sapiens (human)Potency0.50120.00022.621531.4954AID485297
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency4.22840.168316.404067.0158AID720504
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency10.00000.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency50.43910.000627.21521,122.0200AID651741; AID720636; AID743202
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency17.22790.425612.059128.1838AID504891; AID624308; AID624312
tumor susceptibility gene 101 proteinHomo sapiens (human)Potency29.01230.129810.833132.6090AID493005; AID651599; AID651600
DNA polymerase eta isoform 1Homo sapiens (human)Potency67.45550.100028.9256213.3130AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency26.15740.050127.073689.1251AID588590; AID720496
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.72360.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.44440.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency19.60550.031622.3146100.0000AID588579; AID720501
survival motor neuron protein isoform dHomo sapiens (human)Potency0.55760.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency4.46680.00419.962528.1838AID2675
lethal factor (plasmid)Bacillus anthracis str. A2012Potency15.84890.020010.786931.6228AID912
neuropeptide S receptor isoform AHomo sapiens (human)Potency7.94330.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.15450.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency1.12510.002319.595674.0614AID651631; AID651743; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.15450.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Platelet-activating factor receptorHomo sapiens (human)Potency15.848910.000025.781039.8107AID892
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency4.46680.56239.398525.1189AID652106
Nuclear receptor ROR-gammaHomo sapiens (human)Potency18.83360.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency13.35731.000010.475628.1838AID1457
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency100.00003.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.28690.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.19450.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA polymerase beta subunit (EC 2.7.7.6), partialEscherichia coliIC50 (µMol)23.176111.687217.090023.7759AID826
90-kda heat shock protein beta HSP90 beta, partialHomo sapiens (human)IC50 (µMol)14.72180.17369.803229.2701AID712; AID754
nonstructural protein 1Influenza A virus (A/California/07/2009(H1N1))IC50 (µMol)32.70500.200024.4540100.0000AID504329
fMet-Leu-Phe receptorHomo sapiens (human)IC50 (µMol)66.70005.30009.166714.4000AID519
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)IC50 (µMol)14.72180.17369.803229.2701AID712; AID754
14-3-3 protein gammaHomo sapiens (human)IC50 (µMol)0.78120.78120.78120.7812AID711
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
insulin-degrading enzyme isoform 1Homo sapiens (human)EC50 (µMol)54.70502.02605.17858.9430AID588439; AID588681
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PAX8Homo sapiens (human)AC501.55000.04885.435469.1700AID687027
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7Homo sapiens (human)AC507.44000.039815.002550.0000AID743267
LANAHuman gammaherpesvirus 8AC501.99470.042032.4569312.0010AID504725; AID504726; AID504727
S100A4, partialHomo sapiens (human)AC500.23500.23501.76286.0200AID687001
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (258)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (44)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (84)

Assay IDTitleYearJournalArticle
AID94918Antitumor activity against L-1210 leukemia cell line in BDF1 mice after injecting 0.5 mg/kg intraperitoneal dose1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antitumor activity of 9-[(carbamoyloxy)alkyl]anthracyclines: a novel class of anthracycline derivatives.
AID122110Antitumor activity against mice baering P388 leukemia (10e6 cells) implanted ip on day 0, after treatment with three ip doses (8 mg/kg) on day 5,9,13 when tumor became systemic.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Intensely potent morpholinyl anthracyclines.
AID1145038Binding affinity to salmon sperm DNA assessed as first order dissociation rate at pH 7.8 by stop-flow technique in presence of 1 mM Na+ ionic strength1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID138188Compound was evaluated for antitumor activity in mice injected intraperitoneal with leukemia P-388 cells, treated on days 5, 9, and 13 th day at 16 mg/kg1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID97978Dose required to inhibit the DNA synthesis in leukemia L1210 cells1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID104209In vivo screening in M109 syngeneic solid mouse tumor model (i.v.)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds.
AID248336Cytotoxicity against SW620 colon cancer cell line done for 72 h at 37 degree C with compound in MTS assay2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Syntheses and biological activities of disaccharide daunorubicins.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1123695Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.39 mg/kg, ip administered as qd for 1 to 9 days relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID322956Inhibition of synthetic amyloid beta42 oligomer formation by Western blot2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID221147Thermal denaturation for stabilization of helical DNA by the compound1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID135676Compound was evaluated for antitumor activity in mice injected intraperitoneal with leukemia P-388 cells, treated on days 5, 9, and 13th day at 4 mg/kg1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID1123703Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 4 mg/kg, ip administered as single dose for every 4 days up to 13 days relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID261111Cytotoxicity against drug-sensitive K562 cell line by MTS assay2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
AID55161Inhibition of [3H]thymidine incorporation into proliferating L1210 cells.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Intensely potent morpholinyl anthracyclines.
AID379894Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2006Journal of natural products, Dec, Volume: 69, Issue:12
seco-Cycloartane triterpenes from Gardenia aubryi.
AID1123693Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1.56 mg/kg, ip administered as qd for 1 to 9 days relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1123717Genotoxicity in Salmonella typhimurium TA100 assessed as number of revertants by Ames test1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1145041Antitumor activity against mouse P388 cells allografted in mouse assessed as tumor growth inhibition at 0.25 to 10 mg/kg1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID1145032Dissociation constant, pKa of the compound1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID1123710Cardiotoxicity in rat assessed as minimum cumulative drug dose causing electrocardiographic changes1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1123711Genotoxicity in Salmonella typhimurium TA98 assessed as number of revertants by Ames test1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID261113Drug resistance index (ratio of IC50 in drug-resistant cells over drug-sensitive cells)2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
AID379896Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2006Journal of natural products, Dec, Volume: 69, Issue:12
seco-Cycloartane triterpenes from Gardenia aubryi.
AID1145043Binding affinity to salmon sperm DNA assessed as first order dissociation rate at pH 7.8 by stop-flow technique in presence of 201 mM Na+ relative to 1 mM Na+ ionic strength1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID361133Cytotoxicity against human PC3 cells after 48 hrs by MTT assay2002Journal of natural products, Jul, Volume: 65, Issue:7
Cytotoxic germacranolides from Inula verbascifolia subsp. methanea.
AID1130457Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 2 mg/kg, po q4d administered on days 5, 9 and 13 relative to control1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
7-(Aminoethyl) ether and thioether of daunomycinone.
AID104208In vivo screening in M109 syngeneic solid mouse tumor model (i.p.)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds.
AID1145045Retardation factor of the compound in 10% methanol-chloroform by TLC1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID379893Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2006Journal of natural products, Dec, Volume: 69, Issue:12
seco-Cycloartane triterpenes from Gardenia aubryi.
AID1130455Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.78 mg/kg, po qd administered from day 1 to day 9 relative to control1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
7-(Aminoethyl) ether and thioether of daunomycinone.
AID261112Cytotoxicity against doxorubicin-resistant K562 cell line by MTS assay2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
AID1123713Genotoxicity in Salmonella typhimurium 908 assessed as number of revertants by Ames test1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1123716Genotoxicity in Salmonella typhimurium TA98 at >8 ug/plate by Ames test1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1130463Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
7-(Aminoethyl) ether and thioether of daunomycinone.
AID361130Cytotoxicity against human HRT18 cells after 48 hrs by MTT assay2002Journal of natural products, Jul, Volume: 65, Issue:7
Cytotoxic germacranolides from Inula verbascifolia subsp. methanea.
AID23283Partition coefficient (log P) was the log of ratio of concentration in octanol / water partitioned concentration in phosphate buffer at pH 7.4.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Intensely potent morpholinyl anthracyclines.
AID1123694Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.78 mg/kg, ip administered as qd for 1 to 9 days relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1123696Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.2 mg/kg, ip administered as qd for 1 to 9 days relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1123702Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 8 mg/kg, ip administered as single dose on day 5, 9 and 13 relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID379895Cytotoxicity against human PC-3 cells after 48 hrs by MTT assay2006Journal of natural products, Dec, Volume: 69, Issue:12
seco-Cycloartane triterpenes from Gardenia aubryi.
AID170954Compound was evaluated for augmentation of rat liver microsomal oxygen consumption relative to doxorubicin1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID1145039Binding affinity to salmon sperm DNA assessed as first order dissociation rate at pH 7.8 by stop-flow technique in presence of 21 mM Na+ ionic strength1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID322955Inhibition of synthetic amyloid beta-42 oligomerization by ELISA2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1123721Inhibition of DNA synthesis in mouse L1210 cells1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID55638Change in thermal denaturation temperature of calf thymus DNA1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Intensely potent morpholinyl anthracyclines.
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1130462Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
7-(Aminoethyl) ether and thioether of daunomycinone.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1145035Inhibition of Escherichia coli DNA-dependent RNA polymerase assessed as [3H]UMP incorporation into RNA using calf thymus DNA at 0.12 mM by liquid scintillation counting1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID1145040Binding affinity to salmon sperm DNA assessed as first order dissociation rate at pH 7.8 by stop-flow technique in presence of 201 mM Na+ ionic strength1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID138201Compound was evaluated for antitumor activity in mice injected intraperitoneal with leukemia P-388 cells, treated on days 5, 9, and 13th day at 2 mg/kg1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID1145037Binding affinity to salmon sperm DNA assessed as first order dissociation rate at pH 6.2 by stop-flow technique in presence of 21 mM Na+ ionic strength1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID135681Compound was evaluated for antitumor activity in mice injected intraperitoneal with leukemia P-388 cells, treated on days 5, 9, and 13th day at 8 mg/kg1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID361128Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay2002Journal of natural products, Jul, Volume: 65, Issue:7
Cytotoxic germacranolides from Inula verbascifolia subsp. methanea.
AID361131Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay2002Journal of natural products, Jul, Volume: 65, Issue:7
Cytotoxic germacranolides from Inula verbascifolia subsp. methanea.
AID1123720Binding affinity to calf thymus DNA assessed as change in melting temperature1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID166707Inhibition of [3H]uridine incorporation into proliferating L1210 cells.1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Intensely potent morpholinyl anthracyclines.
AID153384Growth Inhibition of P388/0 cell lines.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds.
AID1123722Inhibition of RNA synthesis in mouse L1210 cells1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1145042Binding affinity to salmon sperm DNA assessed as first order dissociation rate at pH 7.8 by stop-flow technique in presence of 21 mM Na+ relative to pH 6.21976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID361132Cytotoxicity against human LNCAP cells expressing androgen receptor after 48 hrs by MTT assay2002Journal of natural products, Jul, Volume: 65, Issue:7
Cytotoxic germacranolides from Inula verbascifolia subsp. methanea.
AID1130461Binding affinity to DNA (unknown origin) assessed as DNA interaction by measuring change in melting temperature1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
7-(Aminoethyl) ether and thioether of daunomycinone.
AID1123701Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 16 mg/kg, ip administered as single dose on day 5, 9 and 13 relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID1145036Binding affinity to salmon sperm DNA assessed as first order dissociation rate at pH 6.2 by stop-flow technique in presence of 5 mM Na+ ionic strength1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Sturcture-activity relationship of daunorubicin and its peptide derivatives.
AID361129Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay2002Journal of natural products, Jul, Volume: 65, Issue:7
Cytotoxic germacranolides from Inula verbascifolia subsp. methanea.
AID248214Cytotoxicity against K562 leukemia cell line done for 72 hr at 37 degree C with compound in MTS assay2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Syntheses and biological activities of disaccharide daunorubicins.
AID97979Dose required to inhibit the RNA synthesis in leukemia L1210 cells1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary antitumor evaluation of 5-iminodoxorubicin.
AID1123704Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 2 mg/kg, ip administered as single dose on day 5, 9 and 13 relative to control1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID720501qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds2012PloS one, , Volume: 7, Issue:10
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (26.32)18.7374
1990's1 (5.26)18.2507
2000's7 (36.84)29.6817
2010's5 (26.32)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.09 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index44.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]